title: [The contribution of genes polymorphism of thrombophilia in clinical variability of hemorrhagic vasculitis].
abstract: BACKGROUND
  The article is devoted to the study of clinical and laboratory characteristics of the current of hemorrhagic vasculitis in children in the Republic of Buryatia.
  
  
  METHODS
  The study included 27 patients aged 7.6 +/- 4.02 years, who conducted clinical and laboratory tests, immunological study of antiphospholipids of antibodies, genetic testing for thrombophilia markers of candidate genes.
  
  
  RESULTS
  The results showed that hemorrhagic vasculitis often affects children of Buryat nationality. In 96% of cases there are mixed clinical forms of the disease. 63% of children of hemorrhagic vasculitis preceded by various factors, a higher percentage of infectious diseases. The first clinical symptom in 63% of patients is a typical purpura hemorrhagic rash. Results of clinical laboratory blood tests revealed no significant deviations. Circulation of lupus anticoagulant was detected in 37% of subjects. The alphaCL IgM detected in 3 children, alphabeta2-GP-I IgA--in 4, alphabeta2-GP-I IgM--in 1 patient. Carriers of thrombophilia polymorphisms were in 95% of children. Noted that homozygous variants of genes polymorphisms of methylenetetrahydrofolatered reductase and plasminogen activator inhibitor-1 correlate with the presence of urinary symptoms and recurrence of the rash.
  
  
  CONCLUSIONS
  The study shows the risk of recurrent flow of hemorrhagic vasculitis and nefritis of Henoch-Schonlein in children with thrombophilia gene polymorphism.
authors.forename: L V
authors.initials: LV
authors.lastname: Zhdanova
authors.forename: L I
authors.initials: LI
authors.lastname: Patrushev
authors.forename: V V
authors.initials: VV
authors.lastname: Dolgikh
authors.forename: A B-Zh
authors.initials: AB
authors.lastname: Bimbaev
authors.forename: O Ch
authors.initials: OCh
authors.lastname: Khoĭkova
mesh_terms: D002648:Child; D002675:Child, Preschool; D005076:Exanthema / Q000503:physiopathology; D005260:Female; D020022:Genetic Predisposition to Disease / Q000453:epidemiology; D006801:Humans; D011695:IgA Vasculitis / Q000150:complications / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D008297:Male; D042965:Methylenetetrahydrofolate Reductase (NADPH2) / Q000235:genetics*; D015166:Monitoring, Immunologic; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011110:Polymorphism, Genetic; D012008:Recurrence; D012426:Russia / Q000453:epidemiology; D019851:Thrombophilia / Q000150:complications / Q000453:epidemiology / Q000235:genetics / Q000276:immunology / Q000503:physiopathology; D014551:Urinary Tract / Q000503:physiopathology
chemical_list: D017395:Plasminogen Activator Inhibitor 1; D042965:Methylenetetrahydrofolate Reductase (NADPH2)